Efficacy of Thermotherapy to Treat Cutaneous Leishmaniasis: A Meta-Analysis of Controlled Clinical Trials

Cardona‐Arias, Jaiberth Antonio; Vélez, Iván Darío; López-Carvajal, Liliana

doi:10.1371/journal.pone.0122569

Cited by 51 publications

(54 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, cryotherapy is increasingly used for the treatment of cutaneous leishmaniasis, demonstrating a similar efficacy with the pentavalent antimony [25] . Another kind of treatment is currently available involving the application of heat, thermotherapy, demonstrating a greater safety and lower cost, especially in the case of contraindications to systemic treatment [26] .…”

Section: Discussionmentioning

confidence: 99%

Clinical Presentation of Cutaneous Leishmaniasis caused by Leishmania major

Remadi

Haouas²,

Chaara³

et al. 2016

Dermatology

View full text Add to dashboard Cite

Background/Aims: The diagnosis of cutaneous leishmaniasis (CL) is based on the microscopic detection of amastigote, isolation of the parasite, or the detection of Leishmania DNA. Nevertheless, since these techniques are time consuming and not usually available in many endemic countries, the diagnosis remains clinical. Consequently, such disease may be overlooked because of its similarity to other skin diseases. The aim of this study is to describe the clinical polymorphism of CL caused by Leishmaniamajor.Methods: A cross-sectional survey was carried out on 166 patients. Diagnoses were made by both microscopic examination of stained tissue-scraping smears and PCR. The Leishmania species was identified by restriction enzyme analysis of the ribosomal internal transcribed spacer 1 region. The clinical polymorphism was analyzed only for patients with a positive diagnosis for CL and L. major as the identified species. Results and Conclusion: Of the 166 patients, 75 patients fit the inclusion criteria. Twelve different types of CL caused by L. major were defined. The most common type was the ulcero-crusted form followed by the papulonodular form and the impetigenous form. The ulcerated, mucocutaneous, lupoid, and sporotricoid forms were less common. The eczematiform, erysipeloid, verrucous, psoriasiform, and pseudotumoral types were represented by a single case. Zoonotic CL caused by L. major can simulate many other skin diseases, which may lead to a significant spread of this disease and increases in morbidity and drug resistance. This large polymorphism may be the result of a complex association between the genetics of the parasite and the immune response of the host.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Presentation of Cutaneous Leishmaniasis caused by Leishmania major

Remadi

Haouas²,

Chaara³

et al. 2016

Dermatology

View full text Add to dashboard Cite

show abstract

“…Pentavalent antimonial drugs have been used since the 1940s as the first‐line therapeutic agents for CL worldwide . A wide variety of treatment alternatives have been inducted into the therapeutic arsenal against CL over the years: Physical therapies: thermotherapy , cryotherapy , laser , photodynamic therapy . Local agents: topical paramomycin , topical imiquimod , topical amphotericin B , 25% podophyllin solution , local infiltration with sodium stibogluconate , hypertonic saline , zinc sulphate , metronidazole . Systemic agents: pentavalent antimonials , azoles (Fluconazole , itraconazole ) pentamidine , zinc sulphate , azithromycin , rifampicin , miltefosine . Alternative/Adjuvant therapies: topical herbal extract (Z‐HE), garlic cream and topical honey . …”

Section: Discussionmentioning

confidence: 99%

Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis: a preliminary report

Mushtaq

Dogra

2016

Dermatologic Therapy

View full text Add to dashboard Cite

Cutaneous leishmaniasis (CL) is a vector-borne tropical disease caused by a heterogeneous group of protozoan parasites that belong to the genus Leishmania. With an annual incidence of 1.5 million new cases, CL is a global health concern mainly in developing countries. The treatment options for CL are numerous but none is optimal. Pentavalent antimonials despite their side effects remain the preferred choice since decades. Alternate new treatment options are being explored to expand the therapeutic armamentarium of CL. In this study, we intend to describe our therapeutic experience with intralesional amphotericin B in the treatment of CL in a series of Indian patients, hitherto not commonly used in old world CL (OWCL). We also endeavour to review the literature on the use of amphotericin B in OWCL. Five consecutive patients diagnosed with cutaneous leishmansis at the out-patient department of Dermatology, Government Medical College, Jammu were treated with weekly injections of intralesional amphotericin B (2.5 mg/mL). Treatment response was assessed at each visit and the cases were followed up for 6 months. All the five patients responded well to the treatment and remained recurrence-free during follow-up. Intralesional amphotericin B was found to be safe and effective treatment for OWCL. Large randomized control trials need to be conducted to establish its efficacy.

show abstract

“…If these results are confirmed in vivo, nanosilver may be appropriate for ulcer treatment [1]. Nanosilver damage DNA, denature proteins and enzymes and produce free radicals and some studies showed that nanosilver is cytotoxic to several different cell lines [1,38]. The teratogenicity of nanosilver in humans is indistinctive and is not reported in the literature but in vivo (animal studies) and in vitro studies showed nanosilver can exhibit a significant level of toxicity [39].…”

Section: Application Of Nano Drugs In Treatment Of Leishmaniasismentioning

confidence: 99%

“…Nano-mediated drug delivery of plant-derived products is one of the most important strategies for the treatment of visceral leishmaniasis (VL) in the absence of adequate anti-leishmanial drugs. Artemisinin has been traditionally used for the treatment of malaria and has been reported to exhibit anti leishmanial and antitumor activities [2,[38][39][40]. Earlier, it has been proved that formulation of artemisinin-loaded nanoparticles improved its activity against L. donovani amastigotes ex vivo [17].…”

Section: Application Of Nano Drugs In Treatment Of Leishmaniasismentioning

confidence: 99%

Application of Nano Drugs in Treatment of Leishmaniasis

Shahcheraghi¹

2016

Glob J Infect Dis Clin Res

View full text Add to dashboard Cite

Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most common form of leishmaniasis is cutaneous leishmaniasis (CL) with 1.5 million new cases per year. Correct diagnosis and characterization of the particular parasite is important for evaluating prognosis and prescribing appropriate treatment. The current management of leishmaniasis is drug treatment of patients, to alleviate disease and vector control to reduce its transmission. Also, current treatments for visceral leishmaniasis are unsatisfactory because of their toxicity, resistance and high cost. The purpose of the present study was to review the application of nano drugs in treatment of leishmaniasis. Materials and Methods:it was used as source of research the following databases: MEDLINE, Cochrane Library, Scielo, PubMed and the database of CAPES.Results: It has been proved nanosilver particles with highly small sizes, have a good penetration into the cutaneous lesions and a good efficacy on leishmaniasis.anti-leishmanial therapy [14][15][16][17]. Although glucantime is commonly used for the treatment of leishmaniasis, it has some side effects including increased liver enzymes and electrocardiogram changes [17]. In addition, the drug is expensive, the injection is painful, and research shows that resistance of parasite to glucantime is growing in different parts of the world [17][18][19][20]. The use of nanotechnology is ever-expanding in today's technologically advanced world. This form of technology has many advantages over existing ones in many fields and medicine is one of them [20]. There are numerous devices and mechanisms developed with the aid of nanotechnology that can help cure diseases/disorders in a much better and more efficient manner [21]. The usefulness of nanotechnology can especially be seen in the treatment of infectious diseases [21,22]. This review has investigated the treatment of leishmaniasis by nano drugs. Nano drugs against leishmaniasisNanotechnology must be applied for curing infectious disease like leishmaniasis [22]. Many drugs have been made and are still being discovered, but the protozoan re-emerges showing drug resistance to the effective medications [23]. Nanotechnology has just managed to show its promise in developing a liposomal formulation called amphotericin B for leishmaniasis but has serious side effects and is not cost effective in developing countries [23][24][25]. Initial, nanodelivery systems for delivering chemotherapeutics were nanodisks impregnanted with amphotericin B, polymericnanoparticle loaded with pentamidine, primaquine, and niosomes, which still need validation at the clinical level [25][26][27][28]. There is an urgent need to take up assignments to use effective nanotechnology devices in combating this infectious disease [25][26][27][28].Different mechanisms were proposed for antimicrobial property of nanoparticles [28]. One mechanism is binding of nanoparticle to sulfur/ phosphorus-containing biomolecules such as proteins and DNA, which leads to...

show abstract

Efficacy of Thermotherapy to Treat Cutaneous Leishmaniasis: A Meta-Analysis of Controlled Clinical Trials

Cited by 51 publications

References 49 publications

Clinical Presentation of Cutaneous Leishmaniasis caused by <b><i>Leishmania major</i></b>

Clinical Presentation of Cutaneous Leishmaniasis caused by <b><i>Leishmania major</i></b>

Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis: a preliminary report

Application of Nano Drugs in Treatment of Leishmaniasis

Contact Info

Product

Resources

About